Compare NUAI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUAI | CTMX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.1M | 642.2M |
| IPO Year | N/A | 2015 |
| Metric | NUAI | CTMX |
|---|---|---|
| Price | $4.40 | $3.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $11.00 | ★ $12.10 |
| AVG Volume (30 Days) | ★ 9.5M | 5.3M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.32 | $1.72 |
| 52 Week High | $9.45 | $8.21 |
| Indicator | NUAI | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 57.67 |
| Support Level | $3.71 | $3.40 |
| Resistance Level | $5.31 | $3.90 |
| Average True Range (ATR) | 0.70 | 0.25 |
| MACD | -0.21 | 0.08 |
| Stochastic Oscillator | 6.85 | 75.23 |
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.